Posted by Michael Wonder on 30 Mar 2023
Renovion receives FDA fast track designation for ARINA-1 for the prevention of BOS progression in lung transplant patients
30 March 2023 - Renovion announced today that the US FDA has granted fast track designation to ARINA-1 for the prevention of bronchiolitis obliterans syndrome progression in adults with a bilateral lung transplant.
ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health.
